Cytokinetics initiates Phase III trial of omecamtiv mecarbil to treat chronic heart failure

US-based late-stage biopharmaceutical company Cytokinetics has initiated its Phase III GALACTIC-HF clinical trial of omecamtiv mecarbil to treat patients experiencing chronic heart failure.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news